Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-MyersSquibb ... KarXT for schizophrenia, which, although positive, was anticipated and thus unlikely to ...
Some results have been hidden because they may be inaccessible to you